Loading
A phase 1/2 trial of LM-108 and Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, active and no longer recruiting.
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05518045 by LaNova Medicines Limited, with 392 participants enrolled, started 2022-08-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: LM-108 and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/